BIOCYTOGEN PHARMA. H YC1 (I54) — Cash Flow Reinvestment Rate
BIOCYTOGEN PHARMA. H YC1 (I54) has a Cash Flow Reinvestment Rate of 0.24x as of December 2025, reinvesting €90.49 Million (capex €87.82 Million plus investments €2.67 Million) from operating cash flow of €370.25 Million. See BIOCYTOGEN PHARMA. H YC1 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BIOCYTOGEN PHARMA. H YC1 Cash Flow Reinvestment Rate (2024–2025)
Historical reinvestment intensity for BIOCYTOGEN PHARMA. H YC1 across 2 annual periods. For the full cash flow conversion analysis, see I54 cash flow metrics.
Annual Cash Flow Reinvestment Rate for BIOCYTOGEN PHARMA. H YC1 (2024–2025)
Year-by-year capital reinvestment analysis for BIOCYTOGEN PHARMA. H YC1. See I54 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.24x | €90.49 Million | €370.25 Million | €87.82 Million | ▲ +35.1% |
| 2024 | 0.18x | €38.22 Million | €211.25 Million | €37.13 Million | — |